See more : Feytech Holdings Berhad (5322.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Acer Therapeutics Inc. (ACER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acer Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ai-Media Technologies Limited (AIM.AX) Income Statement Analysis – Financial Results
- Qatar Electricity & Water Company Q.P.S.C. (QEWS.QA) Income Statement Analysis – Financial Results
- Surge Energy Inc. (ZPTAF) Income Statement Analysis – Financial Results
- JDC Group AG (A8A.DE) Income Statement Analysis – Financial Results
- Sailong Pharmaceutical Group Co., Ltd. (002898.SZ) Income Statement Analysis – Financial Results
Acer Therapeutics Inc. (ACER)
About Acer Therapeutics Inc.
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.26M | 0.00 | 0.00 | 432.12K | -246.30K | 2.91M | 2.56M | 1.27M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.45K | 46.45K | 0.00 | 0.00 | 3.92K | 16.05K | 249.57K | 816.24K | 2.90M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 266.04K | 687.51K | 2.54M |
| Gross Profit | 0.00 | 1.26M | 0.00 | 0.00 | 432.12K | -246.30K | 2.91M | 2.56M | 1.27M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.45K | 46.45K | 0.00 | 0.00 | 3.92K | 16.05K | -16.47K | 128.73K | 363.10K |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | -6.60% | 15.77% | 12.51% |
| Research & Development | 11.92M | 6.51M | 11.85M | 13.85M | 12.45M | 8.73M | 6.50M | 10.04M | 12.12M | 9.18M | 6.32M | 3.34M | 2.58M | 2.11M | 8.39M | 13.07M | 7.61M | 9.89M | 632.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.69M | 10.70M | 10.95M | 16.05M | 9.26M | 5.22M | 3.12M | 4.26M | 3.83M | 3.67M | 2.51M | 0.00 | 2.22M | 2.02M | 0.00 | 0.00 | 5.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.69M | 10.70M | 10.95M | 16.05M | 9.26M | 5.22M | 3.12M | 4.26M | 3.83M | 3.67M | 2.51M | 2.41M | 2.22M | 2.02M | 3.34M | 3.42M | 5.46M | 550.18K | 3.13M | 120.35K | 130.29K | 528.35K | 975.65K | 685.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.63K | 68.70K | 2.15K | 37.91K | 303.68K | 219.94K | 169.30K | 216.62K | 237.16K | 246.15K | 1.82M | 1.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 24.61M | 17.21M | 22.80M | 29.90M | 21.71M | 13.95M | 9.86M | 14.65M | 16.34M | 13.19M | 9.13M | 5.97M | 4.97M | 4.35M | 11.97M | 16.74M | 14.90M | 12.20M | 3.76M | 121.84K | 160.30K | 528.35K | 975.65K | 730.47K |
| Cost & Expenses | 24.61M | 17.21M | 22.80M | 29.90M | 21.71M | 13.95M | 9.86M | 14.65M | 16.34M | 13.19M | 9.13M | 5.97M | 4.97M | 4.35M | 11.97M | 16.74M | 14.90M | 12.20M | 3.76M | 121.84K | 160.30K | 794.38K | 1.66M | 3.27M |
| Interest Income | 1.82K | 49.27 | 13.58K | 471.27K | 412.55K | 14.85K | 0.00 | 0.00 | 15.46K | 14.99K | 280.00 | 932.00 | 1.66K | 1.76K | 100.24K | 477.61K | 688.30K | 81.93K | 5.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 101.43K | 0.00 | 0.00 | 0.00 | 987.00 | 245.06K | 0.00 | 0.00 | 1.98K | 2.27M | 350.30K | 3.14K | 500.65K | 278.13K | 19.98K | 16.10K | 984.00 | 7.32M | 868.93K | 55.06K | 54.16K | 55.40K | 33.71K | 13.95K |
| Depreciation & Amortization | -198.47K | -54.76K | 96.20K | -8.21K | 27.74K | 4.00K | 238.13K | 351.40K | 387.78K | 335.60K | 303.68K | 210.25K | 168.84K | 214.85K | 234.33K | 232.96K | 1.82M | 7.25M | 1.02M | 1.48K | 12.95K | 15.40K | 19.41K | 19.13K |
| EBITDA | -24.55M | -15.88M | -22.73M | -28.34M | -21.25M | -13.95M | -6.70M | -2.57M | -14.66M | -11.53M | -8.83M | -5.76M | -4.80M | -7.32M | -11.77M | -18.10M | -13.23M | -4.95M | -2.74M | -201.83K | -113.49K | -531.89K | -827.39K | -551.31K |
| EBITDA Ratio | 0.00% | -1,270.09% | 0.00% | 0.00% | -4,929.34% | 5,656.94% | -195.37% | -459.26% | -1,152.81% | -910.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -38,961.47% | -28,472.35% | 0.00% | 0.00% | -5,155.33% | -707.07% | -213.13% | -101.37% | -19.00% |
| Operating Income | -24.61M | -15.95M | -22.80M | -29.90M | -21.71M | -13.95M | -7.99M | -12.09M | -15.07M | -11.92M | -9.13M | -5.97M | -4.97M | -4.35M | -11.97M | -16.74M | -14.90M | -12.20M | -3.76M | -117.92K | -144.25K | -544.82K | -846.92K | -367.37K |
| Operating Income Ratio | 0.00% | -1,265.75% | 0.00% | 0.00% | -5,024.81% | 5,662.97% | -275.08% | -473.10% | -1,184.68% | -941.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -36,030.81% | -32,067.06% | 0.00% | 0.00% | -3,012.06% | -898.67% | -218.31% | -103.76% | -12.66% |
| Total Other Income/Expenses | -1.62M | 574.40K | -82.62K | -1.02M | 433.10K | -246.30K | -1.28M | 74.61K | 15.62K | -4.73M | 202.96K | -3.14K | -498.99K | 2.91M | 115.15K | 2.68M | 838.74K | -7.21M | -860.56K | 85.39K | -17.80K | 2.47K | -120.00 | 203.07K |
| Income Before Tax | -26.24M | -15.37M | -22.89M | -29.42M | -21.28M | -14.19M | -7.98M | -12.02M | -15.05M | -16.66M | -8.93M | -5.97M | -5.47M | -1.43M | -11.85M | -14.67M | -14.06M | -19.41M | -4.62M | -32.53K | -162.05K | -542.34K | -847.04K | -164.30K |
| Income Before Tax Ratio | 0.00% | -1,220.16% | 0.00% | 0.00% | -4,924.81% | 5,762.97% | -274.69% | -470.18% | -1,183.45% | -1,315.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,576.68% | -30,261.37% | 0.00% | 0.00% | -830.91% | -1,009.56% | -217.32% | -103.77% | -5.66% |
| Income Tax Expense | 1.62M | -645.31K | 11.81K | -537.75K | -432.12K | 246.30K | 1.04M | -4.74K | 4.13K | 2.31M | -202.96K | 5.97M | 5.47M | 1.43M | 11.85M | 14.67M | 14.06M | 19.41M | 4.62M | -30.33K | 54.91K | 52.93K | 33.83K | -189.12K |
| Net Income | -27.86M | -14.73M | -22.90M | -28.88M | -21.28M | -14.19M | -7.98M | -12.02M | -15.05M | -16.66M | -8.93M | -5.97M | -5.47M | -1.43M | -11.85M | -14.67M | -14.06M | -19.41M | -4.62M | -87.59K | -199.16K | -597.74K | -880.75K | -178.25K |
| Net Income Ratio | 0.00% | -1,168.94% | 0.00% | 0.00% | -4,924.81% | 5,762.97% | -274.69% | -470.18% | -1,183.45% | -1,315.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,576.68% | -30,261.37% | 0.00% | 0.00% | -2,237.24% | -1,240.76% | -239.51% | -107.90% | -6.14% |
| EPS | -1.77 | -1.03 | -2.06 | -2.86 | -2.49 | -3.84 | -11.72 | -21.26 | -39.65 | -91.56 | -113.13 | -77.65 | -93.91 | -33.48 | -329.28 | -642.07 | -764.35 | -363.69 | -2.15K | -385.85 | -4.86K | -13.90K | -18.35K | -3.79K |
| EPS Diluted | -1.77 | -1.03 | -2.06 | -2.86 | -2.49 | -3.84 | -11.72 | -21.26 | -39.65 | -91.56 | -113.13 | -77.65 | -93.91 | -33.48 | -329.28 | -642.07 | -764.35 | -363.69 | -2.15K | -385.85 | -4.86K | -13.90K | -18.35K | -3.79K |
| Weighted Avg Shares Out | 15.77M | 14.27M | 11.12M | 10.09M | 8.56M | 3.69M | 680.67K | 565.35K | 379.63K | 181.92K | 78.94K | 76.87K | 58.24K | 42.83K | 35.99K | 22.84K | 18.39K | 53.38K | 2.15K | 227.00 | 41.00 | 43.00 | 48.00 | 47.00 |
| Weighted Avg Shares Out (Dil) | 15.77M | 14.27M | 11.12M | 10.09M | 8.56M | 3.69M | 680.67K | 565.35K | 379.63K | 181.92K | 78.94K | 76.87K | 58.24K | 42.83K | 35.99K | 22.84K | 18.39K | 53.38K | 2.15K | 227.00 | 41.00 | 43.00 | 48.00 | 47.00 |
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
OLPRUVA™ (sodium phenylbutyrate) kits now available in all dosage strengths and ready to ship to patients OLPRUVA™ (sodium phenylbutyrate) kits now available in all dosage strengths and ready to ship to patients
ACER's Stock Down on Failure of Phase II Study, Cash Updates
ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
7 Penny Stocks With Strong Insider Buying Signals
When it comes to penny stocks, a diligent look at fundamentals and insider activity should be key to your research. After all, penny stocks with strong insider buying can potentially be strong opportunities.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
Here is how Acer Therapeutics Inc. (ACER) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
Here is how Acer Therapeutics Inc. (ACER) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Acer Therapeutics Inc. (ACER) Upgraded to Strong Buy: What Does It Mean for the Stock?
Acer Therapeutics Inc. (ACER) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ACER Down Despite FDA Nod for Urea Cycle Disorders Drug
The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.
Is Acer Therapeutics (ACER) Stock Outpacing Its Medical Peers This Year?
Here is how Acer Therapeutics Inc. (ACER) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Acer Therapeutics to Participate in August and September 2022 Investor Conferences
NEWTON, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that Acer's...
Source: https://incomestatements.info
Category: Stock Reports